Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use by Victoriano Romero et al.
Romero et al. BMC Urology 2014, 14:10
http://www.biomedcentral.com/1471-2490/14/10RESEARCH ARTICLE Open AccessPathology of bladder cancer among diabetic
patients undergoing radical cystectomy with a
history of pioglitazone (Actos) use
Victoriano Romero, Charles Peyton, Ian Gray, Ashok Hemal and Ryan Terlecki*Abstract
Background: Prospective studies suggested an association between pioglitazone (Actos) use and the development
of bladder cancer. Cancer pathology among pioglitazone users has not been characterized. We chose to compare
the surgical pathology among diabetic users and non-users, as well as non-diabetic patients who underwent radical
cystectomy for bladder cancer.
Methods: Our single-center, prospectively-maintained bladder cancer database was reviewed. Patient demographics,
surgical pathology, and outcomes were evaluated. Information regarding diabetic history and use of pioglitazone was
determined from chart analysis and patient interview.
Results: From April 2005 to October 2011, 204 patients undergoing radical cystectomy were identified. Of these, 33
(16.2%) were diabetic and 171 (83.8%) had no history of diabetes. Among diabetic patients, 9 (27.3%) had a history of
pioglitazone use. Median duration of therapy was 14 (6–120) months. Pathology in non-diabetic patients was T1 in 17
(9.9%), T2 in 38 (22.2%), T3 in 44 (25.7%), and T4 in 31 (18.1%). Pathology among diabetic non-users was T1 in 1 (4.2%),
T2 in 7 (29.2%), T3 in 7 (29.2%), and T4 in 4 (16.7%). Pathologic stage among diabetic users was T1 in 1 (11.1%), T2 in 3
(33.3%), T3 in 3 (33.3%), and T4 in 1 (11.1%). Lymph node involvement in non-diabetics, diabetic non-users, and diabetic
users was 25.7%, 33.3%, and 33.3%, respectively. Cancer-specific death was seen in 60.3% of non-diabetics, 58.3% of
diabetic non-users, and 75% of diabetic users.
Conclusions: Diabetics have similar stage distribution regardless of pioglitazone use. Lymph node metastases rates
and cancer specific death were similar across all groups. Additional studies will serve to better characterize this
relationship.
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Peroxisome-proliferator-activator-receptor (PPAR)-γ is
a ligand activated nuclear transcription factor that is
expressed in normal urothelium, but, more importantly,
over-expressed in bladder tumors [1-3]. The three iso-
forms of PPARs (α, γ, and δ) are important targets in
regulating normal adipose proliferation and insulin sen-
sitivity [4,5]. As such, PPAR agonists – thiazolidine-
diones (TZD) – have become a common method of
combating insulin resistance. However, preclinical in-
vestigations have linked pioglitazone (Actos), a PPAR-γ* Correspondence: rterleck@wakehealth.edu
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reproduction in any medium, provided the oragonist thiazolidinedione, to developing bladder tumors
in animal studies [6-8].
In 2005, a large European randomized control trial (PRO-
active) evaluating the effects of piolglitazone in prevention
of macrovascular events noted a non-significant increase in
the number of bladder cancers among piolglitazone users
versus those taking a placebo (14 out of 2605 vs 6 out of
2633, respectively) [9]. Given the aforementioned precli-
nical studies and this clinical observation, the United States
Federal Drug Administration [10] launched a 10-year co-
hort study to evaluate the association between pioglitazone
and bladder cancer [11]. A midterm evaluation of the en-
rolled patients revealed no significant association between
short-term pioglitazone use and bladder cancer; however,l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ciated with an increased risk of developing bladder can-
cer [11]. Another cohort study in France demonstrated
a significant dose-dependent association between pio-
glitizone use and bladder cancer, sparking removal from
the French market and the US Food and Drug Adminis-
tration warning for using pioglitazone in patients with
a current or previous bladder cancer [10,12]. Furthermore,
a recent meta-analysis of the link between pioglitazone
and bladder cancer suggests, “cautious interpretation” of
the limited available data and encourages further investi-
gation [13].
Although there has been considerable interest in the
incidence of bladder cancer after pioglitazone use, a
PubMed search of the peer-reviewed literature fails to
reveal any data characterizing surgical pathologic sta-
ging among bladder cancer patients with a history of pi-
oglitazone use. To better understand the characteristics
of bladder cancers that may develop following pioglita-
zone use, we sought to evaluate tumor staging among
non-diabetics and diabetic users and non-users of pio-
glitazone undergoing cystectomy at our institution.
Methods
We reviewed our Wake Forest University Health Sciences
Institutional Review Board approved, prospectively main-
tained database of patients having undergone radical cys-
tectomy for bladder cancer from April 2005 – October
2011. Patient demographics, medical co-morbidities, me-
dication use, operative details, surgical pathology, and out-
comes were evaluated. Information regarding diabetic
history and use of pioglitazone was gathered from chart
analysis and telephone interview.
Statistical analysis was conducted using GraphPad Prism
software, version 4.0. Student t-tests were used to com-
pare group characteristics/demographics as mean ±
SEM. Multiple Mann–Whitney U signed rank tests (ie:
Kruskal-Wallis tests) were used to compare stage distribu-
tion between groups (i.e., non-diabetics, diabetic users of
pioglitazone, and diabetic non-users). A p < 0.05 was con-
sidered significant. Only statistically significant p-values
were included in data tables.
Results
A total of 204 patients undergoing radical cystectomy by
three different surgeons were identified. Of these, 33
(16.2%) had insulin-dependent diabetes mellitus and 171
(83.8%) had no history of diabetes. Among diabetic pa-
tients, 9 (27.3%) had a history of pioglitazone use, and
all were white males. Twenty-four (72.7%) of diabetics in
this study were not exposed to Actos. Patient demo-
graphics and general co-morbidities are summarized in
Table 1. Not surprisingly, the presence of cardiovascular
disease was significantly higher among diabetic patients(57.6% versus 26.9%, p < 0.01), as was BMI (29.31 versus
26.3, p < 0.05). Median duration of pioglitazone therapy
was 14 months (range 6–120).
Tumor stage distribution is shown in Table 2. There
was a wide distribution of tumor stage within all groups,
with the majority of bladder cancers ranging from T2 –
T4. Surgical pathologic stage distribution among all dia-
betics (eg: combined pioglitazone users and non-users)
tended to be more advanced; however this finding was
not statistically significant. Muscle invasive disease was
not significantly different between non-diabetics, diabetic
non-users, and diabetic Actos users (66.1%, 75%, and 77.8%
respectively, p = 0.51). Lymph node positivity was not sig-
nificantly different between non-diabetics, diabetic non-
users, and diabetic Actos users (25.7%, 33.3%, and 33.3% re-
spectively, p = 0.71). Cancer specific death was not signifi-
cantly different between non-diabetics, diabetic non-users,
and diabetic Actos users (22.2%, 29.2%, and 33.3% respec-
tively, p = 0.37).
Discussion
Pioglitazone (ActosTM) has long been recognized as an
effective medication in the management of diabetes, and
has been previously recorded as a best-selling drug [7].
It has been widely used as both monotherapy and as part
of a multidrug regimen to address insulin resistance. Al-
though, no warnings regarding the potential for urothelial
carcinogenesis were made upon initial release, preclinical
rodent studies demonstrated a propensity for development
of bladder tumors following treatment with PPAR-γ ago-
nists, a phenomenon potentially lessened by urinary
acidification [6]. Additionally, studies on human bladder
tumor specimens have demonstrated an increased density
of PPAR-γ receptors compared to normal bladder tissue,
with increased expression among higher-grade tumors [3].
While preclinical studies demonstrated pro-neoplastic ef-
fects of PPAR-γ agonists, this class of medication received
a largely favorable safety profile due in part to cardiopro-
tective effects [7,9].
At the conclusion of the PROactive study, pioglita-
zone was associated with a significant decrease in all
cause mortality, non-fatal myocardial infarction, and
stroke [9]. Considering only bladder cancer that was
diagnosed a year or more after the onset of the study,
tumors were seen in six patients in the pioglitazone
arm and in three patients in the placebo arm, one of
which was later reported to have benign pathology. This
finding was not statistically significant, and remained non-
significant in 4 years of follow-up [14]. Hillaire-Buys et al.
performed an updated repeat analysis of the PROactive
data excluding one case in the placebo group that actually
showed benign pathology, and only then was a statistically
significant increase in bladder cancer incidence deter-
mined for pioglitazone users [15].
Table 1 Demographics and medical co-morbidities of bladder cancer patients undergoing cystectomy with only
statistically significant p-values shown
All patients p-value Diabetic subgroups p-value
Non diabetic Diabetic Pioglitazone non-users Pioglitazone users
N 171 33 24 9
Age (years ± SEM) 67.7 67.2 66.6 ± 1.5 68.7 ± 1.8
Sex (male) 68.4% 88% 0.009a 88% 100%
Race/ethnicity: No. (%)
White 157 (91.8) 31 (94) 22 (92) 9 (100)
Black 13 (7.6) 1 (3) 1 (4) -
Asian 1 (0.6) - - -
Hispanic - 1 (3) 1 (4) -
Smoking 71 (41.5) 12 (36.4) 5 (20.8) 7 (77.8) 0.012a
CV disease 46 (26.9) 19 (57.6) 0.01a 13 (54.2) 6 (66.7)
Pulmonary disease 26 (15.2) 7 (21.2) 5 (20.8) 6 (66.7)
Creatinine (mg/dL) 1.17 1.21 1.2 ± 0.07 1.23 ± 0.11
BMI 26.3 29.31 0.005a 29.2 ± 1.24 29.5 ± 2.3
astudent t-test.
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study gathered retrospective data on 193,099 diabetic
patients and identified 30,173 pioglitazone users, with 90
of these having developed bladder tumors [11]. Although
the 5-year midterm analysis found that pioglitazone use
for more than 2 years had a weak association with in-
creased cancer risk, there was no statistically significant
short-term use risk and no evidence of a tumor stage
shift [11]. Additional epidemiologic studies led to sus-
pension of the use of pioglitazone in France, and aTable 2 Bladder cancer stage distribution among
non-diabetics and diabetic non-users and users of
pioglitazone (Actos)








T0 18 (10.5) 3 (9.1) 2 (8.3) 1 (11.1)
Ta 7 (4.1) 1 (3) 1 (4.2) -
Tis 16 (9.3) 2 (6) 2 (8.3) -
T1 17 (9.9) 2 (6) 1 (4.2) 1 (11.1)
T2 38 (22.2) 10 (30.3) 7 (29.2) 3 (33.3)
T3 44 (25.7) 10 (30.3) 7 (29.2) 3 (33.3)
T4 31 (18.1) 5 (15.2) 4 (16.7) 1 (11.1)
Non muscle
invasive
58 (34) 8 (24.2) 6 (25) 2 (22.2)
Muscle invasive 113 (66) 25 (75.8) 18 (75) 7 (77.8)
Node positive
disease
44 (25.7) 11 (33.3) 8 (33.3) 3 (33.3)
DM diabetes mellitus.
Comparison of groups found no statistically significant difference.warning in Germany to avoid prescriptions for non-
users [12]. On June 15, 2011, the USFDA officially issued
a similar warning.
Despite the work investigating an association between
pioglitazone and the development of bladder cancer, no
reports have shown a detailed comparison of pathologic
tumor staging and patient outcomes between users of
this medication when compared to other patients. Based
on a PubMed literature search at the time of manuscript
preparation, our study is the first to examine the association
of pioglitazone use on pathologic staging of cystectomy
specimens, surgical presence of lymph node involvement,
or cancer-specific survival. Although our cohort is small,
the cancers associated with pioglitazone use in our series
were unique to male patients. Preclinical rodent studies
have found the same sexual predilection [6]. This may sug-
gest a hormonal or chromosomal factor yet unidentified.
Our cohort also demonstrated a higher propensity for
muscle invasive disease among pioglitazone users. Although
this did not reach statistical significance, perhaps a larger
cohort would better elucidate this relationship.
This investigation was limited by the retrospective na-
ture of the database, and small number of pioglitazone
users identified. Also, the cumulative dose and dose dur-
ation was not fully accounted for, secondary to reliance
on retrospective data and recall bias on the part of pa-
tients. Moving forward, we are collecting this data on
patients and also giving attention to findings such as
urine pH. Information on use of diabetic medications
that could reduce the incidence of bladder cancer should
also be gathered. Metformin, for example, has been
shown in some studies to protect against bladder cancer
development, and the interaction between metformin
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egies for management of Type II diabetes. Future efforts
will also include analysis of those bladder cancer patients
not undergoing cystectomy (e.g., TURBT +/− adjuvant
therapies). We will also aim to determine PPAR-γ receptor
density among cases. Furthermore, drawing data from lar-
ger sources (e.g., SEER database) may serve to shed more
light on this matter.
Conclusions
In our experience, diabetics undergoing radical cystectomy
have similar stage distribution regardless of pioglitazone
use. The rate of lymph node metastases and cancer specific
death was similar across all groups. Additional study and
further follow-up may better characterize this relationship.
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